Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zandelisib - MEI Pharma/Kyowa Kirin

Next Previous
Drug Profile

Zandelisib - MEI Pharma/Kyowa Kirin

Alternative Names: ACC 524; ME-401; PW 143; PWT 143

Latest Information Update: 14 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pathway Therapeutics
  • Developer BeiGene; Kyowa Kirin; MEI Pharma
  • Class Amines; Antineoplastics; Benzimidazoles; Inorganic sulfur compounds; Morpholines; Piperidines; Small molecules; Triazines
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma

Most Recent Events

  • 16 Jan 2025 Case Comprehensive Cancer Center terminates phase I/II clinical trials in Diffuse large B cell lymphoma (First-line therapy, Combination therapy) in USA (PO) due to funding unavailability (NCT04517435)
  • 08 Jun 2023 Updated efficacy and adverse events data from the phase II MIRAGE trial in B-cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 05 May 2023 MEI Pharma terminates a phase I trial in Chronic lymphocytic leukaemia and Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA and Switzerland (PO) due to discontinuation of zandelisib program (NCT02914938)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top